Risk factors for medication-related osteonecrosis of the jaw

T. G. Kwon

doi:10.1007/978-3-662-43733-9_3

Risk factors for medication-related osteonecrosis of the jaw

T. G. Kwon

Department of Dentistry

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The clinician should attempt to determine the risk factors for a disease before treatment in order to prevent disease development. Even though numerous clinical case series have reported Medication-related osteonecrosis of the jaw (MRONJ) after intravenous or oral route administration of bisphosphonates (BPs), evidence-based research regarding risk factors is sparse. Currently, the route of administration, dose and duration of intake, nitrogen-containing BPs, and dental infection/dental invasive procedures can be suggested as risk factors for MRONJ. Recently, a human monoclonal antibody inhibiting osteoclasts, denosumab, has been introduced as an antiresorptive drug. The reported risk of denosumabrelated osteonecrosis of the jaw (DRONJ) seems similar or slightly higher compared with intravenous intake of nitrogen- containing BPs. Dental extractions and oncological dosing could be related to an increased risk of DRONJ. There are also increasing reports of osteonecrosis of the jaw related with antiangiogenic chemotherapeutics.

Original language	English
Title of host publication	Medication-Related Osteonecrosis of the Jaws
Subtitle of host publication	Bisphosphonates, Denosumab, and New Agents
Publisher	Springer Berlin Heidelberg
Pages	27-42
Number of pages	16
ISBN (Electronic)	9783662437339
ISBN (Print)	9783662437322
DOIs	https://doi.org/10.1007/978-3-662-43733-9_3
State	Published - 1 Jan 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/978-3-662-43733-9_3

Cite this

@inbook{3f28307e6c7a44f3ba6c9868e21e0aed,

title = "Risk factors for medication-related osteonecrosis of the jaw",

abstract = "The clinician should attempt to determine the risk factors for a disease before treatment in order to prevent disease development. Even though numerous clinical case series have reported Medication-related osteonecrosis of the jaw (MRONJ) after intravenous or oral route administration of bisphosphonates (BPs), evidence-based research regarding risk factors is sparse. Currently, the route of administration, dose and duration of intake, nitrogen-containing BPs, and dental infection/dental invasive procedures can be suggested as risk factors for MRONJ. Recently, a human monoclonal antibody inhibiting osteoclasts, denosumab, has been introduced as an antiresorptive drug. The reported risk of denosumabrelated osteonecrosis of the jaw (DRONJ) seems similar or slightly higher compared with intravenous intake of nitrogen- containing BPs. Dental extractions and oncological dosing could be related to an increased risk of DRONJ. There are also increasing reports of osteonecrosis of the jaw related with antiangiogenic chemotherapeutics.",

author = "Kwon, \{T. G.\}",

note = "Publisher Copyright: {\textcopyright} Springer-Verlag Berlin Heidelberg 2015.",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-662-43733-9\_3",

language = "English",

isbn = "9783662437322",

pages = "27--42",

booktitle = "Medication-Related Osteonecrosis of the Jaws",

publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Risk factors for medication-related osteonecrosis of the jaw

AU - Kwon, T. G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The clinician should attempt to determine the risk factors for a disease before treatment in order to prevent disease development. Even though numerous clinical case series have reported Medication-related osteonecrosis of the jaw (MRONJ) after intravenous or oral route administration of bisphosphonates (BPs), evidence-based research regarding risk factors is sparse. Currently, the route of administration, dose and duration of intake, nitrogen-containing BPs, and dental infection/dental invasive procedures can be suggested as risk factors for MRONJ. Recently, a human monoclonal antibody inhibiting osteoclasts, denosumab, has been introduced as an antiresorptive drug. The reported risk of denosumabrelated osteonecrosis of the jaw (DRONJ) seems similar or slightly higher compared with intravenous intake of nitrogen- containing BPs. Dental extractions and oncological dosing could be related to an increased risk of DRONJ. There are also increasing reports of osteonecrosis of the jaw related with antiangiogenic chemotherapeutics.

AB - The clinician should attempt to determine the risk factors for a disease before treatment in order to prevent disease development. Even though numerous clinical case series have reported Medication-related osteonecrosis of the jaw (MRONJ) after intravenous or oral route administration of bisphosphonates (BPs), evidence-based research regarding risk factors is sparse. Currently, the route of administration, dose and duration of intake, nitrogen-containing BPs, and dental infection/dental invasive procedures can be suggested as risk factors for MRONJ. Recently, a human monoclonal antibody inhibiting osteoclasts, denosumab, has been introduced as an antiresorptive drug. The reported risk of denosumabrelated osteonecrosis of the jaw (DRONJ) seems similar or slightly higher compared with intravenous intake of nitrogen- containing BPs. Dental extractions and oncological dosing could be related to an increased risk of DRONJ. There are also increasing reports of osteonecrosis of the jaw related with antiangiogenic chemotherapeutics.

UR - https://www.scopus.com/pages/publications/84956762143

U2 - 10.1007/978-3-662-43733-9_3

DO - 10.1007/978-3-662-43733-9_3

M3 - Chapter

AN - SCOPUS:84956762143

SN - 9783662437322

SP - 27

EP - 42

BT - Medication-Related Osteonecrosis of the Jaws

PB - Springer Berlin Heidelberg

ER -

Risk factors for medication-related osteonecrosis of the jaw

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this